Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 154Stomach Neoplasms 23Neoplasms 18Neoplasm Metastasis 17Esophageal Neoplasms 16Esophageal Squamous Cell Carcinoma 12Cholangiocarcinoma 12Adenocarcinoma 11Breast Neoplasms 9Pancreatic Adenocarcinoma 8Colorectal Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Ovarian Neoplasms 7Carcinoma, Pancreatic Ductal 7Biliary Tract Neoplasms 7Lung Neoplasms 6Gallbladder Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Pancreatic Diseases 5Digestive System Neoplasms 5Urinary Bladder Neoplasms 4Triple Negative Breast Neoplasms 4Sarcoma 4Prostatic Neoplasms 4Endocrine Gland Neoplasms 4Digestive System Diseases 4Advanced Pancreatic Cancer 4Rectal Neoplasms 3Neoplasms, Glandular and Epithelial 3Neoplasms by Site 3

Interventions

Gemcitabine 4130-nm albumin-bound paclitaxel 3Pancreaticoduodenectomy 2Oxaliplatin 2Irinotecan 2titanium silicide 1tislelizumab 1sonidegib 1paricalcitol 1mitazalimab 1lenvatinib 1ivosidenib 1irinotecan sucrosofate 1glucoraphanin 1devimistat 1Transurethral Resection of Prostate 1Tissue Banks 1Taxes 1Specimen Handling 1Saline Solution 1S 1 (combination) 1Ropivacaine 1Robotic Surgical Procedures 1Radiomics 1Positron Emission Tomography Computed Tomography 1Parturition 1PEGPH20 1Neoadjuvant Therapy 1Magnetic Resonance Spectroscopy 1Losartan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Ductal Adenocarcinoma × Albumin-Bound Paclitaxel × Gastrointestinal × Clear all
NCT04134468 2020-01-31

MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma

Abramson Cancer Center at Penn Medicine

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡